Vitzthum Frank, Behrens Fritz, Anderson N Leigh, Shaw John H
Dade Behring Marburg GmbH, Emil-von-Behring-Strasse 76, PO Box 1149, 35041 Marburg, Germany.
J Proteome Res. 2005 Jul-Aug;4(4):1086-97. doi: 10.1021/pr050080b.
For several years proteomics research has been expected to lead to the finding of new markers that will translate into clinical tests applicable to samples such as serum, plasma and urine: so-called in vitro diagnostics (IVDs). Attempts to implement technologies applied in proteomics, in particular protein arrays and surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS), as IVD instruments have initiated constructive discussions on opportunities and challenges inherent in such a translation process also with respect to the use of multi-marker profiling approaches and pattern signatures in IVD. Taking into account the role that IVD plays in health care, we describe IVD requirements and needs. Subject to stringent costs versus benefit analyses, IVD has to provide reliable information about a person's condition, prognosis or risk to suffer a disease, thus supporting decisions on treatment or prevention. It is mandatory to fulfill requirements in routine IVD, including disease prevention, diagnosis, prognosis, and treatment monitoring or follow up among others. To fulfill IVD requirements, it is essential to (1) provide diagnostic tests that allow for definite and reliable diagnosis tied to a decision on interventions (prevention, treatment, or nontreatment), (2) meet stringent performance characteristics for each analyte (in particular test accuracy, including both precision of the measurement and trueness of the measurement), and (3) provide adequate diagnostic accuracy, i.e., diagnostic sensitivity and diagnostic specificity, determined by the desired positive and negative predictive values which depend on disease frequency. The fulfillment of essential IVD requirements is mandatory in the regulated environment of modern diagnostics. Addressing IVD needs at an early stage can support a timely and effective transition of findings and developments into routine diagnosis. IVD needs reflect features that are useful in clinical practice. This helps to generate acceptance and assists the implementation process. On the basis of IVD requirements and needs, we outline potential implications for clinical proteomics focused on applied research activities.
多年来,蛋白质组学研究一直有望发现新的标志物,这些标志物将转化为适用于血清、血浆和尿液等样本的临床检测方法,即所谓的体外诊断(IVD)。将蛋白质组学中应用的技术,特别是蛋白质阵列和表面增强激光解吸电离飞行时间质谱(SELDI-TOF MS),作为IVD仪器来实施的尝试,引发了关于这种转化过程中所固有的机遇和挑战的建设性讨论,这些讨论也涉及到在IVD中使用多标志物分析方法和模式特征。考虑到IVD在医疗保健中的作用,我们描述了IVD的要求和需求。在严格的成本效益分析下,IVD必须提供有关一个人的健康状况、预后或患病风险的可靠信息,从而支持治疗或预防决策。在常规IVD中满足要求是强制性的,包括疾病预防、诊断、预后以及治疗监测或随访等。为了满足IVD要求,至关重要的是:(1)提供能够进行明确且可靠诊断的诊断检测,该诊断与干预决策(预防、治疗或不治疗)相关;(2)针对每种分析物满足严格的性能特征(特别是检测准确性,包括测量精度和测量真实性);(3)提供足够的诊断准确性,即诊断敏感性和诊断特异性,这取决于所需的阳性和阴性预测值,而阳性和阴性预测值又取决于疾病发生率。在现代诊断的规范环境中,满足IVD的基本要求是强制性的。在早期阶段满足IVD需求可以支持研究结果和进展及时有效地转化为常规诊断。IVD需求反映了在临床实践中有用的特征。这有助于获得认可并促进实施过程。基于IVD的要求和需求,我们概述了针对侧重于应用研究活动的临床蛋白质组学的潜在影响。